Related Experiment Video

Updated: Jul 16, 2026

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

Quantitative evaluation of human delta opioid receptor desensitization using the operational model of drug action

Edita Navratilova1, Sue Waite, Dagmar Stropova

  • 1Department of Medical Pharmacology, The University of Arizona, Tucson, AZ 85724, USA.

Molecular Pharmacology
|February 27, 2007
PubMed

Insights

Opioid receptor desensitization, a protective mechanism, was investigated. Phosphorylation of Ser363 on human delta opioid receptors (hDOR) was identified as the primary molecular driver of this desensitization process.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cell Signaling

Background:

  • Opioid receptor desensitization is a key factor in opioid tolerance.
  • The precise molecular mechanisms underlying opioid receptor desensitization are not fully understood.
  • Investigating these mechanisms is crucial for understanding sustained opioid signaling.

Purpose of the Study:

  • To elucidate the molecular mechanism of deltorphin II-mediated rapid desensitization of human delta opioid receptors (hDOR).
  • To quantify receptor desensitization using a novel mathematical analysis.
  • To correlate desensitization with specific molecular events like phosphorylation and beta-arrestin2 translocation.

Main Methods:

  • Measurement of guanosine 5'-O-(3-[(35)S]thio)-triphosphate binding and cAMP accumulation inhibition.
  • Development of a mathematical model based on the operational model of agonist action.
  • Analysis of receptor phosphorylation at Ser363, beta-arrestin2 translocation, and receptor internalization.

Main Results:

  • Deltorphin II treatment induced phosphorylation of Ser363, beta-arrestin2 translocation, hDOR internalization, and G protein uncoupling.
  • Mutation of Ser363 to alanine significantly attenuated receptor desensitization.
  • Beta-arrestin2 translocation and receptor internalization were largely unaffected by the Ser363 mutation.

Conclusions:

  • Phosphorylation of Ser363 is the principal mechanism driving hDOR desensitization.
  • This finding provides critical insight into the molecular basis of opioid receptor regulation.
  • Understanding Ser363 phosphorylation's role may inform strategies to manage opioid tolerance.

More Related Videos

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding10:13

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

Published on: June 9, 2017

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

Related Concept Videos

Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower Kd...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.